| Total Health & Wellness Associates | |
|
31700 W 12 Mile Rd Suite 250 Farmington Hills MI 48334-4424 | |
| (734) 368-7154 | |
| Not Available |
| Full Name | Total Health & Wellness Associates |
|---|---|
| Speciality | Psychologist |
| Location | 31700 W 12 Mile Rd, Farmington Hills, Michigan |
| Authorized Official Name and Position | Tracy Renea Juliao (OWNER/LICENSED HEALTH PSYCHOLOGIST) |
| Authorized Official Contact | 7343687154 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Total Health & Wellness Associates Po Box 3052 Farmington Hills MI 48333-3052 Ph: (734) 368-7154 | Total Health & Wellness Associates 31700 W 12 Mile Rd Suite 250 Farmington Hills MI 48334-4424 Ph: (734) 368-7154 |
| NPI Number | 1104151950 |
|---|---|
| Provider Enumeration Date | 10/13/2009 |
| Last Update Date | 01/31/2012 |
| Medicare PECOS PAC ID | 5890962427 |
|---|---|
| Medicare Enrollment ID | O20120121000044 |
News Archive
The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).
Women with new-onset atrial fibrillation have a significantly increased cancer risk for at least 1 year after AF diagnosis, an analysis of Women's Health Study data shows.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104151950 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TH0004X | Psychologist - Health | 6301012980 (Michigan) | Primary |
| Provider Name | Tracy R Juliao |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1447350202 PECOS PAC ID: 7416038922 Enrollment ID: I20080122000608 |
News Archive
The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).
Women with new-onset atrial fibrillation have a significantly increased cancer risk for at least 1 year after AF diagnosis, an analysis of Women's Health Study data shows.
› Verified 5 days ago
| Provider Name | Shannon M Harbin |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1972029676 PECOS PAC ID: 0648507111 Enrollment ID: I20190806002624 |
News Archive
The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).
Women with new-onset atrial fibrillation have a significantly increased cancer risk for at least 1 year after AF diagnosis, an analysis of Women's Health Study data shows.
› Verified 5 days ago
News Archive
The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).
Women with new-onset atrial fibrillation have a significantly increased cancer risk for at least 1 year after AF diagnosis, an analysis of Women's Health Study data shows.
› Verified 5 days ago
Words Of Wellness Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 33730 Freedom Rd, Suite C, Farmington Hills, MI 48335 Phone: 248-675-5131 | |
Trinity Health Connections, Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 25882 Orchard Lake Rd, Suite L-5, Farmington Hills, MI 48336 Phone: 248-426-7299 Fax: 248-325-5846 | |
Art Of Healing Behavioral Services, P.l.l.c. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 22111 Atlantic Pointe, Farmington Hills, MI 48336 Phone: 248-514-7919 | |
Michigan Family Therapy, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32841 Middlebelt Rd, Suite 405, Farmington Hills, MI 48334 Phone: 248-733-4899 Fax: 248-733-4208 | |
Serene Counseling And Wellness Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 25521 Arden Park Dr, Farmington Hills, MI 48336 Phone: 313-409-8060 | |
Mindful Development, Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 36216 Freedom Rd Ste 27, Farmington Hills, MI 48335 Phone: 734-335-0845 | |
Farmington Hills Center For Child Therapy Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32813 Middlebelt Rd Ste L, Farmington Hills, MI 48334 Phone: 248-626-0478 |